Polyethylene glycol loxenatide Medicine 10 June 2020 Extended indication In combination with metformin in patients with type 2 diabetes mellitus. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Polyethylene glycol loxenatide Domain Metabolism and Endocrinology Reason of inclusion New medicine (specialité) Main indication Diabetes Extended indication In combination with metformin in patients with type 2 diabetes mellitus. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Jiangsu Hengrui Portfolio holder Mechanism of action GLP-1 receptor agonist Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks GLP-1 Receptor Agonist Bekostiging mogelijk extramuraal conform andere glp-1 agonisten Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date 2022 Expected Registration 2023 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Verwachte indiening gebaseerd op actual primary completion date fase 3 studie in datum in 2016. Therapeutic value Current treatment options Andere GLP1-agonisten. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a week Dosage per administration 100µg References NCT02477969 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References GIPdatabank Additional remarks Totale GLP-1 klasse in 2017 volgens GIP 12.919 gebruikers. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks